Sonstige Indikationen

Titel
Studie
Jahr

A brief instrument to measure health-related quality of life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

Marschner, N., Wilke, J., Reschke, D., Kaiser, F., Schmoor, C., Grugel, R., Boller, E., 2018.

Epub ahead of print: Journal of Medical Economics 1–19. doi:10.1080/13696998.2018.1484750

ARIE
2018

Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.

OTILIA
2018

Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017.

Ann Oncol 28 (Supplement 5)(956P), 340. doi:10.1093/annonc/mdx372

OTILIA
2017

Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017.

Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372

OTILIA
2017

Was können Registerdaten bei der Nutzenbewertung leisten?

Marschner, N., Jänicke, M., 2017.

Ärztezeitung, Schriftenreihe Interdisziplinäre Plattform zur Nutzenbewertung „Lücken in der Evidenz – was leisten Registerdaten?“ Heft 5, September 2017, ISSN 2364-916X

Registerübergreifend
2017

Die Bedeutung von klinischen Tumorregistern.

Marschner, N., Kaiser-Osterhues, A., 2017.

Im Focus Onkologie 20(9), 42–44. doi:10.1007/s15015-017-3513-6

Registerübergreifend
2017

Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO)

Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017.

ESGO7–0321 (PS19)

OTILIA
2017

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Sehouli, J., Tomè, O., Dimitrova, D., Camara, O., Runnebaum, I.B., Tessen, H.W., Rautenberg, B., Chekerov, R., Muallem, M.Z., Lux, M.P., Trarbach, T., Gitsch, G., 2016.

J. Cancer Res. Clin. Oncol. 143(3), 541–550. doi:10.1007/s00432-016-2307-0

Treosulfan-Studie
2016

Patient-reported outcomes in elderly bevazizumab-treated primary ovarian cancer patients: OTILIA study on behalf of the north-eastern german society of gynaecological oncology.

Sehouli, J., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Mustea, A., 2016.

IGCS-0471

OTILIA
2016

Impact of age on the safety and efficacy of bevacizumab (BEV)-containing therapy in patients (pts) with primary ovarian cancer (OC): Analyses from the OTILIA German non-interventional study on behalf of the North-Eastern German Society of Gynaecological Oncology (NOGGO) Ovarian Cancer Working Group.

Mustea, A., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Reichert, D., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Sehouli, J., 2016.

Ann Oncol 27(suppl_6), 296–312, 867P. doi:10.1093/annonc/mdw374.14

OTILIA
2016

Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice – combined results from four prospective, multicentre cohort studies.

Marschner, N., Potthoff, K., Schnell, R., Tesch, H., Zahn, M.-O., Hegewisch-Becker, S., Jänicke, M., 2016.

Oncol Res Treat 39 (suppl.3)(V174), 43. doi:10.1159/000449050

Indikationsübergreifend
2016

First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer.

Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller, M., Sehouli, J., 2015.

ESMO Annual Meeting (Vienna)

OTILIA
2015

Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015.

Annual Meeting ESGO (Society of Gynaecological Oncology) (0919).

OTILIA
2015

Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Mustea, A., Oskay-Oezcelik, G., Wimberger, P., Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Sehouli, J., 2015.

European Journal of Cancer 51 (suppl 3) 548. 10.1016/S0959-8049(16)31520-9

OTILIA
2015

Bone metastasis in solid tumors in German outpatient centers – data from clinical registries.

Hartmann, H., Fietz, T., Köhler, A., Marschner, N., 2013.

Onkologie 36 (suppl. 7)(P842), 258. doi:10.1159/000356365

Registerübergreifend
2013

Registerübergreifend
2012

Register in der onkologischen Versorgungsforschung.

Klinkhammer-Schalke, M., Marschner, N., Hofstädter, F., 2012.

Der Onkologe 18, 142–150. doi:10.1007/s00761-011-2197-3

Registerübergreifend
2012

Registerübergreifend
2010

Registerübergreifend
2009

Ambulatory care in Germany: Randomized controlled trials meet clinical practice.

Marschner, N., 2009.

Onkologie 32 (suppl 4)(V21), 3. doi:10.1159/000242462

Registerübergreifend
2009

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com